28th Annual Cancer Progress Conference
March 7-8, 2017
Westin New York at Times Square

Tuesday, March 7, 2017

7:00 – 8:00am  Registration and Continental Breakfast

8:00 – 8:15am  Opening Remarks
Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health

Greg Simon, JD, Executive Director of the Biden Cancer Initiative of the Biden Foundation; Former Executive Director of the White House Cancer Moonshot Task Force

9:15 – 10:30am  Microbiome and IO: All Things Great and Small
Moderator:
- Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health

Panelists:
- Luisa Salter-Cid, PhD, VP, Head Immunoscience, Small Molecule Immuno-Oncology & Genomics Discovery, Bristol-Myers Squibb
- Gregory Sieczkiewicz, JD, PhD, Managing Director & Chief IP Counsel, MPM Capital
- Laurence Zitvogel, MD, PhD, Group Leader, Tumor Immunology and Immunotherapy, Institute Gustav Roussy

10:30 – 11:00am  Networking Break

11:00 – 12:15pm  Challenges of IO Drug Development and Commercialization: To PD or Not to PD? And How? Those are the Questions
Moderator:
- Bruce L. Booth, D. Phil., Partner, Atlas Venture

Panelists:
- Jeffrey H. Hanke, PhD, Executive Vice President, R&D and Chief Scientific Officer, TESARO
- Robert Hershberg, MD, PhD, Chief Scientific Officer, Celgene Corporation
- Axel Hoos, MD, PhD, Senior Vice President, Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Alexander Shoushtari, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center

12:15 – 1:30pm  Networking Luncheon
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Moderators/Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 – 2:45pm</td>
<td><strong>Future Role of Non-IO Therapies: The Sad Tale of Neglected Targets and Companies in the Race to IO Domination</strong></td>
<td>Moderator: Joel S. Sandler, PhD, Associate Principal, Defined Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lewis H. Bender, MS, MA, MBA, President and Chief Executive Officer, Intensity Therapeutics, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Axel Hoos, MD, PhD, Senior Vice President, Therapeutic Area Head R&amp;D, Head Immuno-Oncology, GlaxoSmithKline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Russell LaMontagne, MS, President and Chief Executive Officer, Boston Immune Technologies and Therapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Eric Rowinsky, MD, Executive Chairman and President, Rgenix, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Peter Sandor, MD, MBA, Vice President and Global TA Head Oncology, Marketing Strategy, Astellas Pharma, US, Inc.</td>
</tr>
<tr>
<td>2:45 – 4:00pm</td>
<td><strong>Data, Data Everywhere: How to Think About, Interpret and Present the Facts</strong></td>
<td>Moderator: Mark Simon, Partner, Torreya Partners</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Kapil Dhingra, MD, Managing Member, KAPital Consulting, LLC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Robert H. Glassman, MD, Vice Chairman, Credit Suisse Global Health Care Investment Banking</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>4:00 – 4:15pm</td>
<td><strong>Networking Break</strong></td>
<td></td>
</tr>
<tr>
<td>4:15 – 5:30pm</td>
<td><strong>Lung Cancer: The Times They Are a Changin’</strong></td>
<td>Moderator: James Lee, PhD, Senior Consultant, Defined Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Panelists:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Maria Koehler, MD, PhD, Vice President, Strategy, Innovation and Collaborations, Pfizer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Gregory Lubiniecki, MD, Executive Director, Clinical Research Oncology, Merck Research Laboratories</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Charles Rudin, MD, PhD, Chief Thoracic Oncology Service; Sylvia Hassenfeld Chair in Lung Cancer Research; co-Director, Druckenmiller Center for Lung Cancer Research; Professor of Medicine, WCMC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Steve Worland, PhD, President and Chief Executive Officer, eFFECTOR</td>
</tr>
<tr>
<td>5:30 – 7:30pm</td>
<td><strong>Cancer Progress 2017 Reception</strong></td>
<td></td>
</tr>
</tbody>
</table>
Wednesday, March 8, 2017

7:00 – 8:00am  Registration and Continental Breakfast

8:00 – 8:15am  Opening Remarks - Mike Rice, MS, MBA, Principal, Defined Health

8:15 – 9:45 am  Aging and Cancer: Live and Let Die or a Cancer-Free Methuselah?
Moderator:
• Mike Rice, MS, MBA, Principal, Defined Health
Panelists:
• Judith Campisi, PhD, Professor, Buck Institute for Research on Aging
• James DeGregori, PhD, Professor, Dept. of Biochemistry and Molecular Genetics; Courtenay C. and Lucy Patten Davis Endowed Chair in Lung Cancer Research; Deputy Director for Basic Science, University of Colorado Cancer Center

9:45 – 10:00am  Networking Break

10:00 – 11:15am  Treating the Enigmatic Exceptional Responders
Moderator:
• Mike Rice, MS, MBA, Principal, Defined Health
Panelists:
• Isaac Kohane, MD, PhD, Marion V. Nelson Professor & Chair, Department of Biomedical Informatics, Harvard Medical School
• Eric D. Peraksis, PhD, Senior Vice President, Informatics, Takeda Pharmaceuticals
• David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan Kettering Cancer Center

11:15 – 12:30   Novel Modalities: Viruses as Cancer Therapeutics – Converting Bad to Good
Moderator:
• Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health
Panelists:
• John Beadle, MD, Chief Executive Officer, PsiOxus Therapeutics Ltd.
• John C. Bell PhD, Senior Scientist, Ottawa Hospital Research Institute, University of Ottawa
• Robert Coffin, PhD, Chief Executive Officer & Director, Replimune
• Noriyuki Kasahara, MD, PhD, Professor, Departments of Cell Biology & Pathology Co-Leader, Viral Oncology Program, University of Miami (and consultant to Tocagen)

12:30 – 1:45pm  Networking Lunch
1:45 – 3:00 pm  Clinical Trials and Approvals 3.0: How Will New Therapeutic Entities be Developed and Approved in 2025?

Moderator:
- Brian Leyland-Jones, MB BS, PhD, Vice President, Avera Center for Precision Oncology and the Department of Molecular and Experimental Medicine, Avera Cancer Institute, Consulting Professor, Stanford University School of Medicine

Panelists:
- Nathan Caffo, President, Presage Biosciences, Inc.
- Alessandra Cesano, MD, PhD, Chief Medical Officer, NanoString Technologies
- Razelle Kurzrock, MD, Chief, Division of Hematology & Oncology, UC San Diego - Moores Cancer Center
- Jean-François Martini, PhD, MSc, Senior Director, Translational Oncology, Early Development, Translational and Immuno-Oncology (EDTO), Global Product Development, Oncology, Pfizer

3:00 – 4:15 pm  Cancer Drug Pricing: Valuing the Value of Innovation

Moderator:
- Ed Saltzman, Chairman, Defined Health

Panelists:
- Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roy Beveridge, MD, Chief Medical Officer, Humana
- Roger Longman, CEO, Real Endpoints LLC
- Scott Shortenhaus, Director of Advocacy, Professional Relation & Policy, Lilly

4:15 pm  Cancer Progress 2017 Conference Concludes